newsfilter
← Latest News
Business Wire·

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for